Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Withdrawn Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This clinical trial studies genetically modified peripheral blood stem cell transplant in treating patients with HIV-associated non-Hodgkin or Hodgkin lymphoma. Giving chemotherapy before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy or radiation therapy is then given to prepare the bone marrow for the stem cell transplant. Laboratory-treated stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy

Timeline

Start: 2015-02
Primary completion: 2019-02
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	O6-benzylguanine	Small molecule	—	Intravenous
Subject	carmustine	Small molecule	—	Intravenous
Background	Cytarabine	Small molecule	—	Intravenous
Background	Etoposide	Small molecule	—	Intravenous
Background	Melphalan	Small molecule	—	Intravenous

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications